Cy­tori bags Aza­ya drugs in as­set pur­chase; Wood­ford of­fers a mea cul­pa on North­west Bio

• Cy­tori is adding a pair of on­col­o­gy drugs to its port­fo­lio with the ac­qui­si­tions of as­sets from San An­to­nio-based Aza­ya. Aza­ya has been at work on nanopar­ti­cle drugs. Their lead pro­gram is re­served for ATI-0918, “an off-patent, com­plex, gener­ic nanopar­ti­cle li­po­so­mal for­mu­la­tion of dox­oru­bicin hy­drochlo­ride, a wide­ly used chemother­a­peu­tic agent of­ten used to treat breast can­cer, ovar­i­an can­cer, mul­ti­ple myelo­ma, and Ka­posi’s sar­co­ma.” Cy­tori is pay­ing $2 mil­lion in stock and pay­ing off a cou­ple of mil­lion in debt. Aza­ya al­so stands to gain up to $166 mil­lion for a va­ri­ety of mile­stones and deal con­tin­gen­cies. Cy­tori says AI-0918 could be ready for launch in Eu­rope in 2019, if every­thing works out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.